Mandate

Vinge advises Surgical Science in conjunction with a directed new issue of shares valued at SEK 2.7 billion

Surgical Science Sweden AB, listed on Nasdaq First North Growth Market, has performed a directed new issue of shares valued at approximately SEK 2.7 billion at a subscription price of SEK 210.

The subscription price was established through a so-called accelerated book building procedure arranged by Pareto Securities. The net proceeds from the directed issue of shares will primarily be used to finance the acquisition of Simbionix USA Corp which was made public on the same day as the directed new issue of shares. 

Vinge’s team consisted of Anders Strid, Edin Agic (project manager) and Adrian Filipovic.

 

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025